Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families

Movement Disorders

Volumn 22, Issue 1, 2007, Pages 55-61

  Ishihara, Lianna ^a,l   Gibson, Rachel A ^b   Warren, Liling ^c   Amouri, Rim ^d   Lyons, Kelly ^e   Wielinski, Catherine ^f   Hunter, Christine ^g   Swartz, Jina E ^b   Elango, Ramu ^b   Akkari, P Anthony ^c   Leppert, David ^b   Surh, Linda ^b   Reeves, Kevin H ^c   Thomas, Siwan ^b   Ragone, Leigh ^c   Hattori, Nobutaka ^h   Pahwa, Rajesh ^e   Jankovic, Joseph ^g   Nance, Martha ^f   Freeman, Alan ⁱ   Gouider Khouja, Neziha ^d   Kefi, Mounir ^d   Zouari, Mourad ^d   Sassi, Samia Ben ^b   Yahmed, Samia Ben ^d   El Euch Fayeche, Ghada ^d   Middleton, Lefkos ^b   Burn, David J ^j   Watts, Ray L ^k   Hentati, Faycal ^d   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

^d Institut National de Neurologie Tunisia   (Tunisia)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^f Struthers Parkinson's Center   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h JUNTENDO UNIVERSITY   (Japan)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^k The University of Alabama at Birmingham   (United States)

^l UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

G2019S; Genetics; LRRK2; PARK8; Parkinson disease

Indexed keywords

LEUCINE RICH REPEAT KINASE 2;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; EUROPEAN AMERICAN; FEMALE; GENE MUTATION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PENETRANCE; PHENOTYPE; PRIORITY JOURNAL; TUNISIA;

ADULT; AGED; AGED, 80 AND OVER; CROSS-CULTURAL COMPARISON; DNA MUTATIONAL ANALYSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FAMILY HEALTH; FEMALE; GENETIC TESTING; GENOTYPE; GLYCINE; HUMANS; MALE; MIDDLE AGED; MUTATION; NORTH AMERICA; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; SERINE; TUNISIA;

EID: 33847751421     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21180     Document Type: Article

References (35)

1. Gasser T. Genetics of Parkinson's disease. Curr Opin Neurol 2005;18:363-369.
2. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002;51:296-301.
3. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 Cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-607.
4. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44:595-600.
5. Zabetian CP, Samii A, Mosley AD, et al. A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 2005;65:741-744.
6. Bialecka M, Hui S, Klodowska-Duda G, Opala G, Tan EK, Drozdzik M. Analysis of LRRK2 G2019S and I2020T mutations in Parkinson's disease. Neurosci Lett 2005;390:1-3.
7. Aasly JO, Toft M, Fernandez-Mata I, et al. Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol 2005;57:762-765.
8. Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005;365:415-416.
9. Di Fonzo A, Rohe CF, Ferreira J, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson' s disease. Lancet 2005;365:412-415.
10. Lesage S, Ibanez P, Lohmann E, et al. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 2005;58:784-787.
11. Kachergus J, Mata IF, Hulihan M, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005;76:672-680.
12. Paisan-Ruiz C, Lang AE, Kawarai T, et al. LRRK2 gene in Parkinson disease. Neurology 2005;65:696-700.
13. Farrer M, Stone J, Mata IF, et al. LRRK2 mutations in Parkinson disease. Neurology 2005;65:738-740.
14. Mata IF, Taylor JP, Kachergus J, et al. LRRK2 R1441G in Spanish patients with Parkinson's disease. Neurosci Lett 2005;382:309-311.
15. Berg D, Schweitzer KJ, Leitner P, et al. Type and frequency of mutations in the LRRK2 gene in familiar and sporadic Parkinson's disease. Brain 2005;128:2760-2762.
16. Khan NL, Jain S, Lynch JM, et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005;128(Pt 12):2786-2796.
17. Lesage S, Leutenegger AL, Ibanez P, et al. LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. Am J Hum Genet 2005;77:330-332.
18. Skipper L, Li Y, Bonnard C, et al. Comprehensive evaluation of common genetic variation within LRRK2 reveals evidence for association with sporadic Parkinson's disease. Hum Mol Genet 2005;14:3549-3556.
19. Lesage S, Durr A, Tazir M, et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 2006;354:422-423.
20. Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006;354:424-425.
21. Wszolek ZK, Pfeiffer RF, Tsuboi Y, et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 2004;62:1619-1622.
22. Funayama M, Hasegawa K, Ohta E, et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 2005;57:918-921.
23. Ross OA, Toft M, Whittle AJ, et al. Lrrk2 and Lewy body disease. Ann Neurol 2006;59:388-393.
24. Gouider-Khouja N, Belal S, Hamida MB, Hentati F. Clinical and genetic study of familial Parkinson's disease in Tunisia. Neurology 2000;54:1603-1609.
25. Hughes AJ, Ben Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992;42:1142-1146.
26. Hobson DE, Pourcher E, Martin WR. Ropinirole and pramipexole, the new agonists. Can J Neurol Sci 1999;26(Suppl. 2):S27-S33.
27. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
28. Hakonarson H, Gulcher JR, Stefansson K. deCODE genetics, Inc. Pharmacogenomics 2003;4:209-215.
29. Taylor JD, Briley D, Nguyen Q, et al. Flow cytometric platform for high-throughput single nucleotide polymorphism analysis. Biotechniques 2001;30:661-669.
30. Abecasis GR, Cherny SS, Cookson WO, Cardon LR. Merlin-rapid analysis of dense genetic maps using sparse gene flow trees. Nat Genet 2002;30:97-101.
31. Cottingham RW Jr, Idury RM, Schaffer AA. Faster sequential genetic linkage computations. Am J Hum Genet 1993;53:252-263.
32. Nichols WC, Pankratz N, Hernandez D, et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 2005;365:410-412.
33. Deng H, Le W, Guo Y, Hunter CB, Xie W, Jankovic J. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol 2005;57:933-934.
34. Fendri K, Kefi M, Hentati F, Amouri R. Genetic heterogeneity within a consanguineous family involving the LGMD 2D and the LGMD 2C genes. Neuromuscul Disord 2006;16:316-320.
35. Skipper L, Shen H, Chua E, et al. Analysis of LRRK2 functional domains in nondominant Parkinson disease. Neurology 2005;65:1319-1321.